Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | CYT01B + Rucaparib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CYT01B | CYT-0851|CYT0851|CYT 0851 | RAD51 Inhibitor 4 | CYT01B (CYT-0851) is a small molecule that inhibits RAD51-mediated homologous recombination, leading to cell death (AACR Annual Meeting 2019, Abstract 2566). | |
Rucaparib | Rubraca | AG014699|PF-01367338|CO-388|AG14447 | PARP Inhibitor (Pan) 22 | Rubraca (rucaparib) binds to and inhibits PARP, which may result in accumulation of DNA damage and chemosensitization of tumor cells (PMID: 17363489). Rubraca (rucaparib) is FDA approved for use as a maintenance therapy in patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, for treatment in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer harboring deleterious somatic and/or germline BRCA mutations who received 2 or more chemotherapies, and in patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer who received anti-androgen therapy and a taxane-based therapy (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | Advanced Solid Tumor | not applicable | CYT01B + Rucaparib | Preclinical - Cell culture | Actionable | In a preclinical study, CYT01B and Rubraca (rucaparib) synergistically inhibited growth of tumor cell lines in culture (AACR Annual Meeting 2019, Abstract 363). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|